An Oncology biotech pioneering  RAD51 inhibition to treat high replication stress tumors

Author name: admin

Satya to present the preclinical profile of first-in-class RAD51 inhibitors at the Upcoming ESMO Congress – Oct 20-24, Madrid, Spain

  Abstract title SAT-122, a potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models Poster number FPN: 35P Publication category Basic science  Session date and time Sunday, October 22 | 9:00 am-5:00 pm Session location Hall 8 Abstract title: SAT-122, a potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, …

Satya to present the preclinical profile of first-in-class RAD51 inhibitors at the Upcoming ESMO Congress – Oct 20-24, Madrid, Spain Read More »

Satya to Highlight its SOS1 inhibitors that demonstrate best-in-class single agent activity in preclinical models of KRAS driven tumors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA

  Abstract title Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS driven tumors Poster number A099 Session Poster Session A                              Session date and time Thursday, October 12 | 12:30 pm-4:00 pm Session location Level 2, Exhibit Hall D Abstract title: Best in class, potent, SOS1 inhibitors demonstrate single agent activity …

Satya to Highlight its SOS1 inhibitors that demonstrate best-in-class single agent activity in preclinical models of KRAS driven tumors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA Read More »

Satya to present preclinical profile of its KIF18A inhibitors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA

  Abstract title Preclinical profile of novel and potent small molecule inhibitors of KIF18A inhibitors in chromosomally unstable solid tumor lines Poster number A024 Session Poster Session A                              Session date and time Thursday, October 12 | 12:30 pm-4:00 pm Session location Level 2, Exhibit Hall D Abstract title: Preclinical profile of novel and potent small molecule inhibitors …

Satya to present preclinical profile of its KIF18A inhibitors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA Read More »

Satya’s MedChem leadership expanded

Navnath Karche, PhD, a Medicinal Chemist with over 18 years of experience across multiple discovery programs in Oncology, Metabolic Disorders, and CNS therapeutic areas. Navnath previously worked at Dai-Ichi and Lupin, after his PhD from Pune University and post-doc from Rouen, France. Ganesh Gudade, with over 20 years of MedChem experience at Lupin, Glenmark and …

Satya’s MedChem leadership expanded Read More »

Scroll to Top